Pan-hematopoietic expression of the NUP98-HOXD13 (NHD13) myeloid oncoprotein using the Vav promoter in mice leads to myelodysplastic syndrome with 4.5-fold increased marrow HoxA9, 3.5-fold reduced myeloid CFU-GM colonies, 2-fold reduced LSK stem cells, and 3-fold reduced Lin-Sca-1-c-Kit+ (LK) progenitors [16, 18–20]. The gene discussed is HOXA9; the disease is myelodysplastic syndrome.